Literature DB >> 11014938

Treatment of reflux-related and non-reflux-related dysphonia with profound gastric acid inhibition.

L H Willems-Bloemer1, G C Vreeburg, R Brummer.   

Abstract

Thirty-eight patients with dysphonia exceeding 3 months, not caused by trauma, infection, paralysis or allergy, were studied. In all patients a 24-hour ambulatory dual-probe pH monitoring, 5 and 20 cm above the lower oesophageal sphincter was performed. Subsequently they were treated with lansoprazole 30 mg once daily during 6 weeks. A voice range profile, perceptual evaluation of the voice and videolaryngostroboscopy were performed in all patients before and after treatment. A questionnaire about laryngeal symptoms and heartburn was completed on the same two occasions. Thirty-nine percent (15 out of 38) of the patients had an abnormal pH profile and were considered to have reflux-related dysphonia. Only these patients showed a significant improvement in their subjective score on dysphonia (p < 0.05), chronic cough (p < 0.05), dysphagia (p < 0. 05) and heartburn (p < 0.01). Also posterior erythema decreased significantly in these patients (p < 0.01). Only 2 of the 15 subjects did not complain of heartburn.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11014938     DOI: 10.1159/000021546

Source DB:  PubMed          Journal:  Folia Phoniatr Logop        ISSN: 1021-7762            Impact factor:   0.849


  2 in total

1.  The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux.

Authors:  Julian A McGlashan; Lesley M Johnstone; John Sykes; Vicki Strugala; Peter W Dettmar
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-05-28       Impact factor: 2.503

2.  Effects of omeprazole over voice quality in muscle tension dysphonia patients with laryngopharyngeal reflux.

Authors:  Tolga Kandogan; Gökce Aksoy; Abdullah Dalgic
Journal:  Iran Red Crescent Med J       Date:  2012-12-06       Impact factor: 0.611

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.